Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Comtan
Entacapone is a catechol-O-methyltransferase (COMT) inhibitor used as an adjunct to levodopa/carbidopa in the treatment of Parkinson's disease. It helps to prolong the effect of levodopa by blocking its breakdown in the body, thereby reducing motor fluctuations (periods of "off" time) experienced by patients.
Used in conjunction with levodopa/carbidopa to treat Parkinson's disease.
Outcome:
Hypertensive crisis
Mechanism:
Increased catecholamine levels
Outcome:
Decreased entacapone absorption
Mechanism:
Chelation
Outcome:
Reduced levodopa absorption
Mechanism:
Increased gastric motility
Most likely new formulation: extended-release formulation to simplify dosing regimens (2026, 70% confidence)
Based on current usage trends and ongoing clinical trials, entacapone is predicted to remain a relevant treatment option for Parkinson's disease for the foreseeable future with a 85% likelihood of continued FDA approval.
COMT Inhibitor
Nitrocatechol